Regenxbio Inc (RGNX) eyes pivotal sura-vec data this quarter and a Q1 2027 BLA filing for RGX-202, backed by $251 million in cash and runway into late 2027.
Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.
Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.
Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.
The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.
REGENXBIO Inc. (NASDAQ:RGNX) shares tumbled 35% after the U.
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
Aug 24 () - Regenxbio said on Monday the U. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.
Regenxbio (RGNX) does not plan to resubmit the biologics license application for its investigational
This is the newest page. Registered accounts read further back.